ClinicalTrials.gg

Program

UI059

A development code.

Its studies are mostly in Gastroesophageal Reflux · Digestive System Diseases, led by Korea United Pharm..

Furthest: phase 1, since Nov 15, 20233 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Korea United Pharm.32 open or runningphase 1since Nov 15, 2023Nov 15, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 15, 2023First study: phase 1 study in Gastroesophageal RefluxFirst studyNCT06141577 · 8 enrolled · Korea, Republic of
  2. Apr 28, 2024Phase 1 study in Digestive System DiseasesNCT06393881 · 66 planned · Korea, Republic of
  3. Jun 18, 2026Phase 1 study in Gastro Esophageal Reflux DisorderNCT07727629 · 60 planned · South Korea

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07727629Gastro Esophageal Reflux Disorder · South Korea1Not yet recruitingAug 202660
NCT06393881Digestive System Diseases · Korea, Republic of1Not yet recruitingSep 14, 202466
NCT06141577Gastroesophageal Reflux · Korea, Republic of1CompletedNov 7, 20238

How it is read

Names in the registry

  • “UI059”, 3 entries

Codes read as this program: UI059.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.